FDA seeks comments: co-development of two or more investigational drugs to be used in combination
This article was originally published in Scrip
Executive Summary
The US FDA is establishing a public docket to obtain input on methods to co-develop two or more distinct investigational drugs intended to be used in combination to treat a disease or condition (but not as a fixed-dose combination), according to a Federal Register announcement posted 8 June.